NKCFO LLC’s NovoCure NVCR Stock Holding History

NKCFO LLC’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-900	Closed	-$200K	–	100
2021 Q2	$200K	Buy	+900	New	+$175K	0.07%	81

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NKCFO LLC's NVCR Position: Q3 2021 in Review

NKCFO LLC sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 900 shares — an estimated $200K sold.

NKCFO LLC first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $200K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

NKCFO LLC reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
NKCFO LLC sold 900 NovoCure shares in Q3 2021, an estimated $200K.
NKCFO LLC first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
NKCFO LLC's NovoCure position peaked at $200K in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on NKCFO LLC's 13F filing for Q3 2021, filed 21 Oct 2021.